Weight loss shot moves to monthly dosing in new trial

NCT ID NCT07292441

Recruiting now Disease control Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 study tests whether switching to a once-monthly injection of GZR18 can help 500 overweight or obese adults maintain weight loss for an additional 24 weeks. All participants previously completed a year of biweekly GZR18 treatment. The study measures changes in body weight, waist size, and other health markers while everyone follows a regular diet and exercise plan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GZR18 injection
What this could lead to: If successful, this could show that a once-monthly injection helps maintain or continue weight loss over 24 weeks, offering a more convenient option for managing obesity.
What could go wrong: This is an extension study, so participants already benefited from the initial 52-week treatment. Results may not apply to new users, and weight regain or side effects are possible with less frequent dosing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Study site 01
NOT_YET_RECRUITING

Beijing, Beijing Municipality, Beijing, China
Study site 01
RECRUITING

Beijing, Beijing Municipality, Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.